Technology | June 15, 2018

LivaNova Receives FDA Clearance for Memo 4D Semi-Rigid Mitral Annuloplasty Ring

Company also announces first implantation of next-generation device

LivaNova Receives FDA Clearance for Memo 4D Semi-Rigid Mitral Annuloplasty Ring

June 15, 2018 — LivaNova PLC announced it received U.S. Food and Drug Administration (FDA) 510(k) clearance for its Memo 4D semi-rigid mitral annuloplasty ring. The company also confirmed the first implantation of the device.

Memo 4D, LivaNova’s next-generation of the Memo device family, now offers a broader range of ring sizes from 24 to 42mm, allowing an additional patient population with mitral regurgitation (MR) to be treated. Memo 4D is the only annuloplasty ring on market to offer the 42mm size, according to LivaNova1. Larger size rings facilitate repair in the presence of severe degenerative MR like Barlow’s disease or enlarged annuli.

Additional features of Memo 4D include:

  • ReChord chordal guide system accelerates procedure times, while providing a standardized approach to neochordae implantation;
  • New ring design offers improved dimensions to treat enlarged annuli and reduce the risk of systolic anterior motion (SAM);
  • True semi-rigid stability and flexibility to ensure a natural behavior; and
  • Gradual saddle shape optimizes the physiological geometry in enlarged annuli.

The first Memo 4D implant was performed by Sreekumar Subramanian, M.D., FACS, of TriStar Cardiovascular Surgery at TriStar Centennial Medical Center in Nashville.

“Memo 4D simplifies and standardizes degenerative complex mitral valve repair, facilitates minimally invasive surgical approaches and preserves the mobility of the mitral valve leaflets,” said Subramanian. “The new larger sizes allow us to treat more patients and pathologies while providing the potential to further improve patient outcomes. With Memo 4D, surgeons can optimize mitral repair procedures rather than replacing the entire mitral valve.”

For more information: www.livanova.com

Reference

1. Measures correspond to intercommissural distance.

Related Content

News | Heart Valve Technology

May 19, 2022 — A study of 1-year outcomes in the largest cohort to date of Harmony transcatheter pulmonary valve (TPV) ...

Home May 19, 2022
Home
News | Heart Valve Technology
May 5, 2022 – Foldax, Inc. has announced that the first patients have been enrolled in the Drugs Controller General of ...
Home May 05, 2022
Home
News | Heart Valve Technology

April 27, 2022 — The U.S. Food and Drug Administration (FDA) has issued a Class I recall for the Medtronic Harmony ...

Home April 27, 2022
Home
News | Heart Valve Technology
March 2, 2022 – An international study led by a researcher from Tel Aviv University offers a novel technology that can ...
Home March 02, 2022
Home
News | Heart Valve Technology
February 28, 2022 - Foldax, Inc. has announced the presentation of results from the first animal study of its ...
Home February 28, 2022
Home
News | Heart Valve Technology
February 14, 2022 — SMT (Sahajanand Medical Technologies Limited) has announced the publication of Hydra Transcatheter ...
Home February 14, 2022
Home
News | Heart Valve Technology

December 13, 2021 - Foldax Inc. announced that the Drugs Controller General of India (DCGI), India’s regulatory body for ...

Home December 13, 2021
Home
News | Heart Valve Technology

November 9, 2021 — New five-year data from the SURTAVI trial found that there was no difference in all-cause mortality ...

Home November 09, 2021
Home
Feature | Heart Valve Technology

July 8, 2021 – Xeltis announced it started the first pivotal trial for a synthetic polymer restorative pulmonary valve ...

Home July 08, 2021
Home
News | Heart Valve Technology

June 2, 2021 – LivaNova announced June 1 it successfully completed the initial closing of the divestiture of its heart ...

Home June 02, 2021
Home
Subscribe Now